[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rct":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,74,111,139,173,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100646636","phase-3-anti-pcsk9-antibody-tafolecimab-and-anti-pd-1-antibody-sintilimab-combined-with-neoadjuvant-chemoradiotherapy-for-pmmr-mss-locally-advanced-rectal-cancer--a-prospective-multicenter-randomized-open-label-parallel-controlled-trial-100646636",false,"NCT07686796","Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR\u002F MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial","Inclusion Criteria:\n\n1. Age 18 to 75 years, any sex.\n2. Histologically confirmed rectal adenocarcinoma, determined to be pMMR (proficient mismatch repair) or MSS (microsatellite stable) by immunohistochemistry and\u002For genetic testing; clinical stage cT3\u002FT4 or cN+; distal tumor margin ≤ 12 cm from the anal verge; and eligible for surgical resection.\n3. No evidence of distant metastases.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n5. Adequate hematologic and biochemical function: absolute neutrophil count ≥ 1.5 × 10⁹\u002FL, hemoglobin ≥ 90 g\u002FL, platelets ≥ 100 × 10⁹\u002FL, ALT\u002FAST ≤ 2.5 times the upper limit of normal (ULN), creatinine ≤ 3.0 × ULN.\n6. Anticipated good compliance and provision of written informed consent.\n\nExclusion Criteria:\n\n1. Known allergy or severe adverse reaction to any study drug, including tafolecimab, PD-1 inhibitor (sintilimab), capecitabine, oxaliplatin, or any excipients.\n2. Rectal cancer confirmed as dMMR (deficient mismatch repair) or MSI-H (microsatellite instability-high).\n3. Pregnant or breastfeeding women, or patients of childbearing potential who refuse to use effective contraception during the study.\n4. Other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, papillary thyroid carcinoma, or other malignancies considered cured after adequate treatment.\n5. Prior anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, immunotherapy, or local surgical excision.\n6. Previous treatment with a PCSK9 inhibitor for any indication.\n7. Severe or uncontrolled neurological disease, psychiatric disorder, or cognitive impairment that, in the investigator's judgment, would affect informed consent or protocol adherence.\n8. Severe cardiovascular or cerebrovascular disease, including but not limited to: unstable angina, myocardial infarction, coronary revascularization, or stroke within 6 months before enrollment; clinically significant arrhythmia requiring treatment or left ventricular ejection fraction (LVEF) \\\u003C 50%; New York Heart Association (NYHA) class III or IV heart failure.\n9. Active infection requiring long-term systemic therapy (e.g., antibiotics, antivirals, or antifungals).\n10. Active autoimmune disease, or requirement for long-term systemic immunosuppressive therapy or corticosteroids (at a dose equivalent to prednisone \\> 10 mg\u002Fday).\n11. Known history of human immunodeficiency virus (HIV) infection, or active syphilis, or active pulmonary tuberculosis.\n12. Active hepatitis B (HBsAg positive and HBV DNA \\> 200 IU\u002FmL or \\> 1000 copies\u002FmL) or active hepatitis C (HCV RNA positive).\n13. Any other clinical condition that, in the investigator's opinion, could interfere with study assessments, increase treatment risk, or lead to premature study discontinuation (including but not limited to severe alcohol or drug abuse).","ALL","18 Years","75 Years",{"count":19,"type":20},148,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab (an anti-PD-1 inhibitor) versus neoadjuvant chemoradiotherapy combined with sintilimab alone in patients with pMMR\u002FMSS locally advanced rectal cancer. The primary endpoint is the complete response (CR) rate, including the pathological complete response (pCR) rate in patients who undergo surgery after neoadjuvant therapy, and the clinical complete response (cCR) rate in patients managed with a watch-and-wait strategy. Secondary endpoints include major pathological response (MPR) rate, objective response rate (ORR), downstaging rate, R0 resection rate, tumor regression grade, sphincter preservation rate, disease-free survival (DFS), overall survival (OS), and safety.",[26,27,28,29,30,31,32],"Local Advanced Rectal Cancer","PD-1 Inhibitor","PCSK9 Inhibitor","RCT","Radiotherapy","Capecitabine","Oxaliplatin","NOT_YET_RECRUITING","2026-07-06",{"date":36,"type":37},"2026-07-07","ACTUAL",{"date":39,"type":20},"2027-01-01",{"date":41,"type":20},"2035-01-01",{"name":43,"class":44},"Guangdong Provincial People's Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":15,"minAge":4,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100606695","designing-a-smoking-intervention-for-youth-smokers-100606695","NCT07178899","Designing a Smoking Intervention for Youth Smokers","Designing a Smoking Intervention for Youth Smokers Using Q-Methodology: A Pilot Randomized Controlled Trial","Inclusion Criteria (Phase 1):\n\n* Hong Kong citizens\n* Have ever habitually used conventional cigarettes in the past year\n* Not using cigarettes for the past 7-30 days\n* Aged 25 or below (parental consent is required for participants under 18 years old)\n* No barriers in communicating in Cantonese and reading and writing Chinese\n* Quit smoking without using cessation services\n\nInclusion Criteria (Phase 3):\n\n* Hong Kong citizens\n* Have ever habitually used conventional cigarettes in the past year\n* Received at least 4 weeks of smoking cessation service before enrolling into the study\n* abstained from tobacco use for 7 days without concurrent use of any cessation services\n* Aged 25 or below (parental consent is required for participants under 18 years old)\n* No barriers in communicating in Cantonese and reading and writing Chinese\n\nExclusion Criteria (Phase 1 \\& 3):\n\n* Have unstable physical or psychological conditions as advised by doctors or counsellors\n* Are users of illicit drugs (e.g., heroin, marijuana, ketamine, etc.)\n* Have become pregnant in the past two months\n* unable to communicate in Cantonese and read Chinese\n\nInclusion Criteria (Phase 2) (for SC counsellors) :\n\n* SC counsellors from local SC clinics under HKU Youth Quit Line, Tung Wah Group of Hospitals Integrated Center on Smoking Cessation and United Christian Nethersole Community Health Service",true,"25 Years",{"count":56,"type":20},100,[58],"NA","This study aims to develop a typology-based intervention delivered by smoking cessation (SC) counsellors to prevent smoking relapse in ex-smokers who recently quit. The two main research questions include (1) Can a typology-based smoking relapse prevention intervention be feasible and accepted by the smokers and SC counsellors who deliver the new intervention? (2) What is the preliminary evidence on the efficacy of the typology-based smoking relapse prevention to increase tobacco abstinence in ex-smokers who have recently quit? If the intervention shows at least a small effect size (i.e. risk ratio\\>1.3), or the intervention is feasible while modifications can potentially increase the efficacy, a future definitive RCT is warranted.",[61,62,29],"Smoking (Tobacco) Addiction","Young Adult",[64,62,29],"Smoking Cessation","2026-05-29",{"date":67,"type":37},"2026-06-02",{"date":69,"type":20},"2026-06-05",{"date":71,"type":20},"2027-06-30",{"name":73,"class":44},"The University of Hong Kong",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":45},"100622551","continuous-vital-sign-monitoring-versus-routine-spot-checks-in-patients-after-non-cardiac-surgery-100622551","NCT07385092","Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery","The Effect of Continuous Monitoring Versus Routine Spot-checks on Altered Vital Signs in Patients Recovering From Non-cardiac Surgery on Normal Wards: the \"COME ON, NOW!\" Trial","COME ON NOW","Inclusion Criteria:\n\nConsenting patients ≥45 years scheduled for elective non-cardiac (abdominal and thoracic) surgery with planned postoperative admission to a normal ward after an overnight stay in an advanced post-anesthesia care unit.\n\nExclusion Criteria:\n\n* Emergency surgery\n* Pregnancy\n* Impossibility to perform continuous monitoring with the Radius VSM sensor (Masimo, Irvine, CA)\n* Atrial fibrillation\n* Patients designated Do Not Resuscitate, or are receiving end-of-life care","45 Years",{"count":84,"type":20},264,[58],"The \"COME ON, NOW!\" trial is a randomized, single-center trial in patients recovering from non-cardiac surgery on normal wards investigating whether continuous vital sign monitoring - compared to routine spot-checks by nurses - reduces the total duration of abnormal vital signs per hour during the first 48 hours after admission to the normal ward.",[88,89,90,29,91],"Vital Sign Monitoring","Post Operative Complications","Non-cardiac Surgery","Anesthesiology",[93,94,95,96,97,98,99,100],"continuous vital signs","vital signs","vital sign monitoring","post-operative care","anesthesiology","anesthesia","hypotension","post-operative complications","RECRUITING","2026-02-27",{"date":104,"type":37},"2026-03-02",{"date":106,"type":37},"2026-02-24",{"date":108,"type":20},"2026-12-31",{"name":110,"class":44},"Universitätsklinikum Hamburg-Eppendorf",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":45},"100621717","phase-2-perioperative-ivonescimab-plus-s-1-and-oxaliplatin-sox-for-locally-advanced-gastric-or-gej-adenocarcinoma-100621717","NCT07374250","Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma","Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) Versus SOX Alone for Locally Advanced Gastric or GEJ Adenocarcinoma: A Multicenter Randomized Phase II Study","Huaxi","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Histologically confirmed gastric or gastroesophageal junction (G\u002FGEJ) adenocarcinoma.\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n4. Clinically staged as T3-4a N+ M0 by computed tomography (CT) or magnetic resonance imaging (MRI).\n5. Considered eligible for curative resection.\n6. No prior antitumor therapy for the current disease.\n7. Adequate organ function, including hepatic, renal, and bone marrow function, as per prespecified laboratory criteria.\n8. Expected survival of ≥6 months.\n\nExclusion Criteria:\n\n1. Known mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumor.\n2. Uncontrolled hypertension, defined as systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg despite optimized antihypertensive therapy, or hypertension complicated by acute events (e.g., hypertensive crisis, hypertensive encephalopathy) that cannot be stably controlled.\n3. Tumor lesions with a bleeding tendency, including but not limited to: active ulcerative tumor lesions, hematemesis within 2 months prior to informed consent, high risk of major gastrointestinal bleeding as determined by the investigator.\n4. History of thromboembolic or arterial\u002Fvenous vascular events within 6 months prior to enrollment, such as cerebrovascular events (including transient ischemic attack), deep vein thrombosis, or pulmonary embolism.\n5. Gastrointestinal perforation or gastrointestinal obstruction within 6 months prior to enrollment.",{"count":120,"type":20},154,[122],"PHASE2","The purpose of this clinical trial is to evaluate whether perioperative ivonescimab in combination with S-1 and oxaliplatin (SOX) is effective in treating locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study will also assess the safety profile of this treatment regimen.\n\nPrimary Objective:\n\nTo determine whether perioperative ivonescimab plus SOX improves the pathological complete response (pCR) rate compared with SOX alone in patients with locally advanced gastric or GEJ adenocarcinoma.\n\nStudy Design:\n\nParticipants will be randomly assigned to receive either ivonescimab plus SOX or SOX alone to evaluate the potential added benefit of ivonescimab in this setting.\n\nParticipation Details:\n\nParticipants will receive the assigned treatment (ivonescimab plus SOX or SOX alone) every 21 days for approximately 4 months.\n\nThey will visit the clinic once every 3 weeks for evaluations, laboratory tests, and monitoring.\n\nParticipants will be asked to keep a daily diary to record any symptoms or side effects experienced during the study.",[125,29],"Gastric Cancer",[127,128,129],"gastric cancer","Ivonescimab","neoadjuvant treatment","2026-01-24",{"date":132,"type":37},"2026-01-28",{"date":134,"type":20},"2026-02-01",{"date":136,"type":20},"2027-12-31",{"name":138,"class":44},"Sichuan University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":159,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":45},"100591018","phase-2-efficacy-of-ipsc-derived-motor-neuron-cells-xs228-in-subacute-spinal-cord-injury-a-phase-ii-randomized-controlled-trial-100591018","NCT06974968","Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial","A Phase II Clinical Study Evaluating the Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells (XS228 Cell Injection) in Patients With Subacute Spinal Cord Injury","Inclusion Criteria:\n\n* Age: 18 to 65 years (inclusive), regardless of gender.\n\nEtiology: Cervical (C4) to lumbar (L2) spinal cord injury (SCI) caused by traumatic injury or surgery-related factors.\n\nSeverity:\n\nClassified as ASIA Impairment Scale (AIS) Grades A, B, or C. MRI-confirmed evidence of spinal cord injury.\n\nDisease Stage:\n\nPrimary SCI occurring 14 to 60 days prior to screening (subacute phase).\n\nContraception:\n\nParticipants of childbearing potential (male and female) must agree to use effective non-hormonal contraceptive methods during the trial and for 6 months after trial completion.\n\nCompliance:\n\nVoluntarily participate in the clinical study. Ability to understand and comply with study procedures. Participant or legal guardian can provide written informed consent.\n\nExclusion Criteria:\n\n* Neurological Inability\n\nPrimary spinal cord injury (SCI) during screening with concomitant severe traumatic brain injury precluding neurological function assessment.\n\nRespiratory\u002FCirculatory Instability\n\nHigh cervical SCI (C1-C3) causing respiratory\u002Fcirculatory compromise requiring endotracheal intubation or tracheostomy.\n\nLife-Threatening Multiorgan Dysfunction\n\nConcurrent severe injuries to other organ systems with life-threatening dysfunction.\n\nUnstable Thoracoabdominal Injuries\n\nInjuries to lungs, liver, kidneys, spleen, etc., deemed unstable by the investigator.\n\nPrior Spinal Pathology\n\nHistory of SCI or coexisting spinal disorders (e.g., ankylosing spondylitis, spinal deformities, primary\u002Fmetastatic spinal tumors, spinal vascular malformations, syringomyelia).\n\nLocal Infection\u002FIncreased ICP\n\nActive infection at the lumbar puncture site or intracranial hypertension during screening.\n\nSevere Infections\n\nSepsis, septic shock, or severe pneumonia (per IDSA\u002FATS 2007 diagnostic criteria).\n\nConfounding Neurological\u002FPsychiatric Conditions\n\nParkinson's disease, severe dementia, myasthenia gravis, stroke, Guillain-Barré syndrome, diabetic neuropathy, or other conditions interfering with study assessments.\n\nCardiac Abnormalities (any of the following):\n\nCongestive heart failure (NYHA Class III\u002FIV). Severe uncontrolled arrhythmias (e.g., sick sinus syndrome, third-degree AV block).\n\nUnstable angina or acute myocardial infarction within 3 months prior. Pulmonary Complications\n\nPulmonary hypertension, pulmonary embolism, or suspected embolism during screening.\n\nUncontrolled Hypertension\u002FHypotension\n\nSystolic BP \\>160 mmHg or diastolic BP \\>100 mmHg; or systolic BP \\\u003C90 mmHg or diastolic BP \\\u003C60 mmHg.\n\nActive Autoimmune Diseases\n\nRequiring immunosuppressants (e.g., uncontrolled hyperthyroidism, systemic lupus erythematosus).\n\nImmunosuppressant Non-Compliance\n\nUnwillingness or inability to use immunosuppressants per protocol.\n\nLaboratory Abnormalities (any of the following):\n\nALT\u002FAST \\>2×ULN or total bilirubin \\>2×ULN. eGFR \\\u003C60 mL\u002Fmin\u002F1.73m² (CKD-EPI 2021 formula). APTT\u002FPT \\>2.5×ULN (without anticoagulants). Platelets \\\u003C100×10⁹\u002FL or hemoglobin \\\u003C90 g\u002FL. Allergy\n\nHistory of severe allergies or hypersensitivity to trial drug\u002Fexcipients (human albumin, lactated Ringer's solution).\n\nInfectious Diseases\n\nHBsAg+ with HBV DNA \\>1000 IU\u002FmL; HCV-Ab+; HIV-Ab+; or TP-Ab+. Lumbar Puncture Refusal\n\nUnwillingness to undergo intrathecal administration procedures. Pregnancy\u002FLactation\n\nFemales who are pregnant or breastfeeding. Malignancy\n\nActive malignancy or anticancer therapy within 5 years prior. Recent Clinical Trial Participation\n\nEnrollment in another drug trial within 3 months prior. Investigator Discretion\n\nAny condition deemed unsuitable for participation by the investigator","65 Years",{"count":148,"type":20},60,[122],"Purpose: This clinical trial is studying an investigational cell therapy called XS228-a lab-made stem cell product designed to help repair damaged nerves in the spinal cord. The goal is to see if XS228 is safe and can improve movement, sensation, and function in people with recent spinal cord injuries.\n\nStudy Treatment: XS228 contains specialized nerve-supporting cells derived from human stem cells. These cells are injected into the spinal fluid (intrathecal administration) in a single dose.\n\nWho Can Join? Adults aged 18-65 with a spinal cord injury (thoracic or lumbar level) that occurred 2-12 weeks before enrollment. Participants must have severe but incomplete paralysis (ASIA Impairment Scale Grade A , B or C).\n\nStudy Plan:\n\nPhase II (Main Study): About 60 participants will be randomly assigned to receive either XS228 or a placebo (inactive solution) in a 2:1 ratio.\n\nFollow-up: Patients will be monitored for 1 year, with regular check-ups to assess safety, nerve function, and recovery progress.\n\nWhat Researchers Are Looking For:\n\nPrimary Goal: Measure changes in leg and arm function using the ASIA Motor Score at 6 months.\n\nSecondary Goals:\n\nImprovement in ASIA Impairment Scale (AIS) grade (e.g., from \"complete\" to \"incomplete\" paralysis).\n\nRecovery of sensation and bladder\u002Fbowel control. Safety (monitoring for side effects like infections or immune reactions). Exploratory Tests: MRI scans and biomarker tests in spinal fluid to see if the treatment helps nerve regrowth.\n\nWhy This Study Matters: If successful, XS228 could become the first stem cell therapy to promote meaningful recovery in spinal cord injury patients. Currently, no treatments exist to repair nerve damage-this trial aims to change that.",[152,153,154,155,156,157,158,29],"Spinal Cord Injury","Safety","Efficacy","Clinical Trial","Induced Pluripotent Stem Cells","Human Motor Neuron Progenitor","Transplantation",[152,153,160,161,156,162,158,29],"efficacy","clinical trial","Human motor neuron progenitor","2025-11-19",{"date":165,"type":37},"2025-11-25",{"date":167,"type":20},"2028-05-25",{"date":169,"type":20},"2031-05-26",{"name":171,"class":172},"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","INDUSTRY",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":15,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":45},"100574800","safety-and-efficacy-of-connecting-the-residual-ear-to-the-cartilage-scaffold-in-first--vs-second-stage-surgery-100574800","NCT06763991","Safety and Efficacy of Connecting the Residual Ear to the Cartilage Scaffold in First- vs. Second-Stage Surgery","Safety and Efficacy of Connecting the Residual Ear to the Cartilage Scaffold in First- vs. Second-Stage Surgery : a Protocl of a Randomized Controlled Trial in Non-expanded Auricular Reconstruction for Concha-type Microtia","Inclusion Criteria:\n\nAll consecutive patients between 6 and 30 years with a congenital concha-microtia8, admitted to our hospital are potentially eligible, and enrollment in the study will be based on the following criteria.\n\n1. Patients were fully informed about the purpose, modalities and risks associated with this study, signed an informed consent form and were willing to be followed up.\n2. Contrast-enhanced computed tomography (CT) scan shows he or she has 3.Patients can tolerate general anesthesia without severe chronic organic or mental illness.\n\nExclusion Criteria:\n\n1. Patients combined with other ear diseases such as ear fistula, titis media, etc.\n2. Patients receive other unrelated ear surgeries during the study\n3. Skin in the surgical area with infection, ulceration, and scarring.","6 Years","30 Years",{"count":183,"type":20},78,[58],"Eligible patients will be admitted from the outpatient clinic to complete the relevant examinations after admission（Preoperative routine examination and chest CT）. The baseline parameters will be registered when admitted to hospital, including case number, diagnosis, sex, age, height, weight, and underlying medical conditions. Patients have at least 12 hours to consider participation in the study and will be given the opportunity to ask questions about the study. Written informed consent will be obtained by the surgical resident or the surgeon after admission to the hospital.\n\nRandomization will be done by relevant member . After inclusion, patients will be allocated to one of the two study groups (First-stage Connection or Second-stage Connection) using an online randomization program. The perioperative care will be the same for all included patients.Surgery will be performed by experienced surgeons, with non-expanded ear reconstruction using autologous rib cartilage. The surgery normally comprises two stages. After each surgery, details and duration of the surgery will be documented. For each stage of surgery, patients are scheduled for visits about 3-6 months. In addition, after the total surgery, patients are to fill out 'Glasgow Benefit Inventory' and 'Patient and Observer Scar Assessment Scale'.",[187,188,29,189,190,191],"Microtia","Outcome Assessment","Surgery Related Complications Rate","Treatment Outcome","Reconstruction","2025-05-15",{"date":194,"type":37},"2025-05-16",{"date":196,"type":20},"2025-06-01",{"date":198,"type":20},"2027-02-20",{"name":200,"class":44},"Sichuan Provincial People's Hospital",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":45},"100573625","effect-of-blue-light-blocking-on-reducing-manic-symptoms-in-bipolar-disorder-100573625","NCT06748716","Effect of Blue Light Blocking on Reducing Manic Symptoms in Bipolar Disorder","Effect of Blue Light Blocking on Reducing Manic Symptoms in Bipolar Disorder: a Randomized Placebo-controlled Trial BLUME (Blue Light Filtering in Manic Episodes)","BLUME","Inclusion Criteria:\n\n* Patients hospitalized with manic symptoms in HUG\n* Diagnostic of Bipolar Disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria\n* aged 18-70 years\n\nExclusion Criteria:\n\n* previous knowledge of blue-blocking glasses\n* not consenting to participate\n* severe eye disease or traumatic injury affecting both eyes.\n* withdrawal symptoms from any drug or alcohol at the time of admission (the start of the intervention will be delayed until withdrawal symptoms have ceased)","70 Years",{"count":211,"type":20},96,[58],"This study will be a randomized controlled trial (RCT) measuring the efficacy of wearing blue-blocking glasses (orange glasses) on manic symptoms in a population of patients suffering from Bipolar Disorder (BD), hospitalized for a manic episode on 10 days compared to non-filtering glasses (clear glasses, placebo) in addition to pharmacological treatment as usual.\n\nThe primary objective of this study is to evaluate the efficacity of orange glasses on improving manic symptoms in adult patients presenting BD in comparison with placebo. The primary outcome will be the change of total score of the Young Mania Rating Scale (YMRS) from baseline to day 10. Secondary objectives will be change in sleep quality, in motor activity (patterns of activity and rest), impact on psychotics symptoms, kinetics of the decrease of the manic symptoms from inclusion to the study and impact on maximal administered antipsychotic medication dosage ; they will be explored.\n\nThe investigators hypothesize that orange glasses is more effective than placebo in improving manic symptoms as an adjuvant treatment.\n\nThis project will take place in Alizé unit which is a newly conceived specialized ward dedicated to treating BD, at the HUG. The methodology has been developed in collaboration with the center of clinical research (CRC). The study will be conducted in accordance with established ethical and data management\u002Fprotection practices.",[215,216,217,218,219,220,29,221],"Bipolar","Manic","Bipolar Disorder (BD)","Dark Therapy","Actigraphy","Mania","Virtual Darkness","2024-12-18",{"date":224,"type":37},"2024-12-27",{"date":226,"type":20},"2025-04-01",{"date":228,"type":20},"2028-04-01",{"name":230,"class":44},"Rayan NASSERDINE"]